# Pfizer Inc: overview

PFE · NYSE · CIK 78003 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pfe.md) · [Financials](/companies/pfe/financials.md) · [Filings](/companies/pfe/filings.md) · [Insiders](/companies/pfe/insiders.md)

Latest reported revenue: [$15.03bn](/filings/0000078003-26-000095.md) for Q2 FY2026, three months to 2026-06-28, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:Revenues, accession 0000078003-26-000095).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [17.7](/filings/0000078003-25-000150.md) | [17.8 d](/filings/0000078003-26-000026.md) | [13.7](/filings/0000078003-26-000054.md) | [14.7](/filings/0000078003-26-000095.md) | [16.7](/filings/0000078003-25-000150.md) | [17.6 d](/filings/0000078003-26-000026.md) | [14.5](/filings/0000078003-26-000054.md) | [15.0](/filings/0000078003-26-000095.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [25.2%](/filings/0000078003-25-000150.md) | [2.3% d](/filings/0000078003-26-000026.md) | [21.6%](/filings/0000078003-26-000054.md) | [19.9%](/filings/0000078003-26-000095.md) | [21.3%](/filings/0000078003-25-000150.md) | [(9.4%) d](/filings/0000078003-26-000026.md) | [18.6%](/filings/0000078003-26-000054.md) | [(1.6%)](/filings/0000078003-26-000095.md) |
| Diluted EPS | $ per share | [0.78](/filings/0000078003-25-000150.md) | not reported | [0.52](/filings/0000078003-26-000054.md) | [0.51](/filings/0000078003-26-000095.md) | [0.62](/filings/0000078003-25-000150.md) | not reported | [0.47](/filings/0000078003-26-000054.md) | [(0.04)](/filings/0000078003-26-000095.md) |
| Free cash flow | $bn | [6.1 d](/filings/0000078003-25-000150.md) | [5.8 d](/filings/0000078003-26-000026.md) | [1.8](/filings/0000078003-26-000054.md) | [(1.2) d](/filings/0000078003-26-000095.md) | [4.0 d](/filings/0000078003-25-000150.md) | [4.5 d](/filings/0000078003-26-000026.md) | [2.2](/filings/0000078003-26-000054.md) | [0.3 d](/filings/0000078003-26-000095.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [73.6](/filings/0000078003-24-000039.md) | [91.8](/filings/0000078003-24-000039.md) | [50.9](/filings/0000078003-24-000039.md) | [63.6](/filings/0000078003-26-000026.md) | [62.6](/filings/0000078003-26-000026.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [29.8%](/filings/0000078003-24-000039.md) | [34.2%](/filings/0000078003-25-000054.md) | [4.2%](/filings/0000078003-26-000026.md) | [12.6%](/filings/0000078003-26-000026.md) | [12.4%](/filings/0000078003-26-000026.md) |
| Diluted EPS | $ per share | [3.85](/filings/0000078003-24-000039.md) | [5.47](/filings/0000078003-25-000054.md) | [0.37](/filings/0000078003-26-000026.md) | [1.41](/filings/0000078003-26-000026.md) | [1.36](/filings/0000078003-26-000026.md) |
| Free cash flow | $bn | [29.9](/filings/0000078003-24-000039.md) | [26.0](/filings/0000078003-25-000054.md) | [4.8](/filings/0000078003-26-000026.md) | [9.8](/filings/0000078003-26-000026.md) | [9.1](/filings/0000078003-26-000026.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pfe/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $12.75bn | 529,670,433 |  | Added +31,412,883 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.96bn | 372,149,852 |  | Added +2,719,840 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $7.39bn | 307,090,897 |  | Added +5,501,032 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $3.25bn | 135,275,782 |  | Added +1,714,040 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.87bn | 119,235,030 |  | Added +2,500,335 |
| [Fisher Asset Management, LLC](/funds/850529.md) | 2026-06-30 | $2.63bn | 109,067,291 |  | Added +4,102,864 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $2.32bn | 96,345,452 |  | Added +3,660,082 |
| [NORGES BANK](/funds/1374170.md) | 2026-06-30 | $1.48bn | 61,505,586 |  | New +61,505,586 |
| [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $1.42bn | 59,084,573 |  | Reduced −2,941,979 |
| [Bank of New York Mellon Corp](/funds/1390777.md) | 2026-06-30 | $1.39bn | 57,879,546 |  | Added +3,999,646 |

## Recent filings

[All 4,571 filings](/companies/pfe/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-04 | 11:04 ET | [10-Q](/filings/0000078003-26-000095.md) | Quarterly report, period 2026-06-28 | 0000078003-26-000095 |
| 2026-08-04 | 11:02 ET | [8-K](/filings/0000078003-26-000094.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000078003-26-000094 |
| 2026-06-18 | 17:17 ET | [8-K](/filings/0000078003-26-000087.md) | 7.01 Regulation FD disclosure | 0000078003-26-000087 |
| 2026-06-18 | 11:07 ET | [8-K](/filings/0000078003-26-000085.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000078003-26-000085 |
| 2026-05-05 | 11:03 ET | [10-Q](/filings/0000078003-26-000054.md) | Quarterly report, period 2026-03-29 | 0000078003-26-000054 |
| 2026-05-05 | 11:01 ET | [8-K](/filings/0000078003-26-000053.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000078003-26-000053 |
| 2026-04-27 | 21:16 ET | [8-K](/filings/0000078003-26-000044.md) | 5.07 Shareholder vote results | 0000078003-26-000044 |
| 2026-03-12 | 13:05 ET | [DEF 14A](/filings/0000078003-26-000033.md) | Proxy statement, period 2026-04-23 | 0000078003-26-000033 |
| 2026-02-26 | 17:44 ET | [10-K](/filings/0000078003-26-000026.md) | Annual report, period 2025-12-31 | 0000078003-26-000026 |
| 2026-02-13 | 17:09 ET | [SCHEDULE 13D/A](/filings/0000078003-26-000022.md) | Ownership report, active investor, amended | 0000078003-26-000022 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000078003-26-000026.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-28, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ad579d03-9e11-49eb-b108-ebcd8c1909bd)

## About the filer

- CIK: 78003
- Tickers: PFE
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:20 ET. No prices; not investment advice.